<DOC>
	<DOCNO>NCT00592475</DOCNO>
	<brief_summary>To evaluate safety IV conivaptan stable euvolemic hypervolemic cirrhotic patient , characterize effect IV conivaptan hepatic hemodynamic response patient cirrhosis .</brief_summary>
	<brief_title>A Study Assess Safety Effects Intravenous ( IV ) Conivaptan Hepatic Hemodynamic Response Cirrhotic Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve write Informed Consent appropriate privacy language per national regulation must obtain subject legally authorize representative prior studyrelated procedure ( include withdrawal prohibit medication , applicable ) Subject euvolemic hypervolemic ( edematous ) secondary cirrhosis Subject clinical evidence portal hypertension presence esophageal varix , ascites Clinical evidence volume depletion dehydration Subject history bleed esophageal varix within three month start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>conivaptan</keyword>
	<keyword>Liver Cirrhosis</keyword>
	<keyword>Hypertension , Portal</keyword>
</DOC>